Due to the complexity of tumor biology, tumor drug development is full of challenges. Compared with other diseases, Hematological malignancies require multi-omics platforms (M: morphology, I: immunology, C: cytogenetics, M: molecular biology, etc.) to provide necessary information for disease diagnosis, treatment, prognosis, etc., and rely on the services provided by the central laboratory.

KingMyLab has established a sound MICM and other multi-omics platforms, which can fully support the research of biomarkers related to Hematological malignancies drug development. At present, we have helped more than 300 clinical research projects of Hematological malignancies , involving small molecules, monoclonal antibody/double antibody and other macromolecules, CAR-T (chimeric antigen receptor T cell) and other therapies, covering diseases such as leukemia, lymphoma and multiple myeloma.